MAAT INDEX

CLAIM #22670 · EMR (EMR) · 2024Q1 earnings call · Feb 7, 2024 · due Dec 31, 2024

And I think there's enough demand-driven activity that will give us confidence in the sustained mid-single-digit kind of exit rate on process on the total company orders at the end of the year.

Lal Karsanbhai · CEO

PENDING
graded after results covering Dec 31, 2024 are reported

In context

reholders, whether they're government in the Middle East or public shareholders in the West. So just wondered your thoughts, Lal, on the kind of sustainability of that high single-digit orders growth in process that you saw in Q1. Should we expect that to moderate over the next sort of 12 months or so? And does that then pull the backlog down with it? Or the book-to-bill was so high that the backlog can still grow with moderating orders? Lal Karsanbhai: Yes. It's a great question, Julian. I just returned from the Middle East where our team spent -- India and the Middle East, so our team spent time with significant customers in Saudi Arabia, Abu Dhabi, Qatar. And I can tell you that the environment is very robust, predominantly around sustainability and energy transition, those 2 elements. And I think there's enough demand-driven activity that will give us confidence in the sustained mid-single-digit kind of exit rate on process on the total company orders at the end of the year. So at this point, we've been thinking and analyzing this now for about three quarters or so. But we haven't seen any kind of deceleration in the process, particularly in the spaces that you're asking about. As a matter of fact, we continue to see very disciplined spending, very intentional around core elements of automation that can differentiate production around reliability, efficiency, productivity, of course, and safety. And that hasn't waned yet. And I don't -- we don't foresee that as we go through the year. Julian Mitchell: That's helpful. Thank you. And then just a much more sort of near-term fiddly question. Just looking at the second quarter guide on Slide 10, so the EPS at the midpoint is going up maybe $0.02 sequentially from Q1 despite a decent revenue and volume increase seq

Verify independently

SEC filings for EMR · Claim quote is verbatim from the 2024Q1 earnings call.